A study published in Nature Communications describes the development of antibiotic nanodelivery systems that use proteins from bacteriophages to target specific bacterial pathogens. These systems enhance the effectiveness of antibiotics by delivering them directly to the site of infection, significantly improving therapeutic outcomes. The research focuses on two ESKAPE pathogens—K. pneumoniae and S. aureus—by engineering nanodelivery systems that use bacteriophage receptor-binding proteins (RBPs) and cell-wall binding domains (CBDs) to guide antibiotics to their targets. The systems were tested against carbapenem-resistant K. pneumoniae (CRKP) and methicillin-resistant S. aureus (MRSA), showing a 16- to 32-fold increase in efficacy compared to free antibiotics. The nanodelivery systems demonstrated high specificity, biocompatibility, and the ability to target infection sites effectively. Additionally, the systems were found to be biocompatible and re-applicable, with no significant toxicity or immune response observed in mice. The study highlights the potential of phage-derived targeting proteins in improving the therapeutic efficacy of antibiotics against difficult-to-treat infections. The results suggest that these nanodelivery systems could be a promising strategy for combating antibiotic-resistant bacteria.A study published in Nature Communications describes the development of antibiotic nanodelivery systems that use proteins from bacteriophages to target specific bacterial pathogens. These systems enhance the effectiveness of antibiotics by delivering them directly to the site of infection, significantly improving therapeutic outcomes. The research focuses on two ESKAPE pathogens—K. pneumoniae and S. aureus—by engineering nanodelivery systems that use bacteriophage receptor-binding proteins (RBPs) and cell-wall binding domains (CBDs) to guide antibiotics to their targets. The systems were tested against carbapenem-resistant K. pneumoniae (CRKP) and methicillin-resistant S. aureus (MRSA), showing a 16- to 32-fold increase in efficacy compared to free antibiotics. The nanodelivery systems demonstrated high specificity, biocompatibility, and the ability to target infection sites effectively. Additionally, the systems were found to be biocompatible and re-applicable, with no significant toxicity or immune response observed in mice. The study highlights the potential of phage-derived targeting proteins in improving the therapeutic efficacy of antibiotics against difficult-to-treat infections. The results suggest that these nanodelivery systems could be a promising strategy for combating antibiotic-resistant bacteria.